Most entries in this ingredient series document an absence. This one documents the opposite problem: hexapeptide-11 has better mechanistic science than almost anything else on a beauty ingredient list, published outside the cosmetic journals, and the thing that science actually says is not what the products say.
PubMed returns five records, searched 2026-09-11. Two are primary studies of the peptide. One is an in vitro comparison of peptide mixtures that includes it. Two are broader articles — one on pigmentation management, one on hyaluronic acid technology — where it appears among other ingredients.
Five is a small number in absolute terms. In this category it is a large one, and unusually, the strongest of them was published in a mainstream redox biology journal rather than a trade title.
What it actually is
Phe-Val-Ala-Pro-Phe-Pro — FVAPFP. PubChem CID 24998056, formula C36H48N6O7, molecular weight 676.8.
It was originally isolated from yeast extract and later synthesised to high purity, which both primary papers state. Two prolines and two phenylalanines in six residues make it an unusually rigid, hydrophobic little molecule compared with the lysine-rich peptides that dominate this shelf.
It carries no fatty tail. That is a real difference from palmitoyl tripeptide-1 and the other palmitoylated actives, where the tail exists specifically to get the molecule through the barrier, and it leaves the penetration question open in a different way.
It is also not a GHK derivative. Nothing from the copper peptide literature applies here.
The 2015 paper, in full
Sklirou et al., Redox Biology, August 2015 (PMID 25974626), from the cell biology department at the University of Athens with co-authors at Korres and Lonza.
In normal human diploid lung and skin fibroblasts, hexapeptide-11 showed no significant toxicity and produced dose- and time-dependent activation of genes for the proteasome, autophagy, chaperones and antioxidant responses. Nrf2 — the master transcription factor for the cell's antioxidant defences — accumulated in the nucleus. Proteasome subunit expression and peptidase activity rose. The peptide protected fibroblasts against oxidative-stress-mediated premature senescence.
That is a coherent, plausible, well-measured story, and it is more than most of this category can show.
The same abstract contains two sentences that product pages never quote.
It induced the activity of extracellular MMPs. Matrix metalloproteinases are the enzymes that degrade collagen and elastin; their induction by ultraviolet light is the central mechanism in the standard account of photoageing. An ingredient sold for firmness that raises MMP activity is not straightforwardly a contradiction — MMPs also remodel and repair, and the paper reports no net collagen measurement — but it is a tension inside the ingredient's own primary evidence, and it belongs in any honest summary.
It suppressed cell migration. In a wound-healing frame that would be read as a drawback.
And one clause carries the only human data: at in vivo skin deformation assays in human subjects it improved skin elasticity. No subject count, no control, no duration, no effect size. That is a mention, not a trial, and it is the entire clinical record of this ingredient.
The mechanism nobody puts on a box
The earlier paper is the more revealing one. Gruber, Ludwig and Holtz, Journal of Cosmetic Science, 2013 (PMID 23578831), written from Arch Personal Care with a Lonza correspondence address — the supplier describing its own ingredient.
Its stated mechanism: the peptide reversibly downregulates ATM and p53 protein expression in fibroblasts and dermal papilla cells, at concentrations between 0.1% and 1.0%. The paper explains the logic clearly. ATM activates p53 by direct phosphorylation; p53 moves cells with DNA damage into senescence, out of reproduction. Damp that signal and cells keep dividing, which reads as delayed ageing in a dish.
p53 is also the most-studied tumour-suppressor protein in human biology, and its job is precisely to stop damaged cells dividing. The 2013 authors emphasise that the effect is reversible and dose-dependent, and that no small peptide had previously been shown to do this — they present the reversibility as the point of interest.
No inference beyond the papers is offered here. What can be stated is the record: the mechanism a supplier proposes for this ingredient is the temporary suppression of a DNA-damage checkpoint in skin cells; the experiments are in cultured cells; there is no long-term human safety study of the ingredient, and no product literature mentions the mechanism at all. A shopper comparing peptide actives has no way to encounter this, because it is stated only in the primary source.
Where it sits against other peptides
Wu et al., Skin Pharmacology and Physiology, 2021 (PMID 33849044), tested five cosmeceutical peptides individually and in mixtures against hydrogen-peroxide-induced senescence in human skin fibroblasts. Hexapeptide-11's optimal concentration for hydroxyproline content — a proxy for collagen — was 400 µg/mL, the joint highest of the five tested, and it was a component of the best-performing mixture alongside carnosine, acetyl tetrapeptide-5 and acetyl hexapeptide-3.
All of that is cell culture. The concentration is a dish concentration, not a formula percentage, and the two numbers are not interchangeable — a point the SNAP-8 entry works through in detail.
The MMP finding, put in proportion
The 2015 paper's report that hexapeptide-11 induces extracellular MMP activity deserves a measurement of its own, because the significance of that sentence depends entirely on what the wider literature does with MMP induction.
Searched the same day on the same database: 513 records join matrix metalloproteinases to photoageing in a title or abstract. That body of work is, in outline, the standard account of how skin ages in sunlight — ultraviolet exposure induces MMPs, MMPs degrade the dermal matrix, and the visible result accumulates. A great deal of cosmetic science, including much of the argument for retinoids, is built on inhibiting that induction.
Against that, 1,420 records join Nrf2 to skin, which is the pathway the same paper reports the peptide activating, and which is a genuinely well-founded protective mechanism.
So the ingredient's one strong primary paper reports it doing both things at once: switching on the protective machinery that a 1,420-record literature supports, and switching on the degradative enzymes that a 513-record literature blames for the appearance being treated. The paper does not reconcile them and reports no net matrix measurement in skin. Neither does any product page.
This is stated as an open question, not as a warning. MMPs also do necessary remodelling work, the experiments were in cultured cells at dish concentrations, and nothing here establishes what happens in skin. But an ingredient whose own best paper contains an unexplained result should not be sold as though it does not.
Products and labels
Hexapeptide-11 appears in firming serums, eye products and some scalp products, usually among several peptides. The supplier's own 2013 paper puts its active range at 0.1% to 1.0% in cell culture, which is the only public number attached to it and is not a formulation percentage.
That is worth saying plainly, because the two numbers look alike and are not: a concentration that acts on fibroblasts in a dish is applied directly to the cells, while a percentage in a cream must survive the formulation and then cross the stratum corneum, and this peptide carries no fatty tail to help it do so. The SNAP-8 entry works the same arithmetic through for a peptide where more of the numbers are public.
No Cosmetic Ingredient Review safety assessment naming this peptide could be located.
What the evidence does not show
No randomised controlled trial. No wrinkle, firmness or elasticity endpoint measured against a vehicle in a designed study. No penetration data for intact human skin. No long-term safety data for an ingredient whose proposed mechanism is checkpoint suppression. And no disclosed concentration on any finished product, which makes the 0.1–1.0% range in the supplier's paper impossible to compare against anything on a shelf.
Sources and dates
Opened 2026-09-11: PubMed E-utilities search for hexapeptide-11 in both hyphenations, all fields, five records retrieved and classified; full abstracts of PMID 25974626 (Sklirou et al. 2015), PMID 23578831 (Gruber et al. 2013) and PMID 33849044 (Wu et al. 2021), including author affiliations; the remaining two records (PMID 36342738, PMID 35486441) read by title and classified as broader articles rather than studies of this peptide; PubChem compound record CID 24998056 for sequence, formula and molecular weight. The proportion section was produced by two further PubMed counts run in the same session: matrix metalloproteinase with photoageing or photoaging in a title or abstract (513 records) and Nrf2 with skin in a title or abstract (1,420). Both are raw database counts, cited as a measure of how much has been published rather than of how well, and neither is a claim about this peptide. Corrections go to the contact page; the review standard is on the testing notes page.